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Abstract
Background: Despite multidisciplinary treatment, lung cancer remains a highly lethal disease due
to poor response to chemotherapy. The identification of therapeutic agents with synergistic effects
with traditional drugs is an alternative for lung cancer therapy. In this study, the synergistic effects
of arsenic trioxide (As2O3) with cisplatin (DDP) on A549 and H460 non-small cell lung cancer
(NSCLC) cells were explored.
Methods: A549 and H460 human lung cancer cells were treated with As2O3 and/or DDP. Cell
growth curves, cell proliferation, cell cycle, and apoptosis of human cancer cell lines were
determined by the 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT)
method, clonogenic assay, and flow cytometry (FCM). Apoptosis was further assessed by TUNEL
staining. Cell cycle and apoptosis related protein p21, cyclin D1, Bcl-2, bax, clusterin, and caspase-
3 were detected by western blot.
Results: MTT and clonogenic assay showed As2O3 within 10-2 μM to 10 μM exerted inhibition on
the proliferation of NSCLC cells, and 2.5 μM As2O3 exerted synergistic inhibition on proliferation
with 3 μg/ml DDP. The combination indices (CI) for A549 and H460 were 0.5 and 0.6, respectively,
as confirmed by the synergism of As2O3 with DDP. FCM showed As2O3 did not affect the cell cycle.
The G0/G1 fraction ranged from 57% to 62% for controlled A549 cells and cells treated with As2O3
and/or DDP. The G0/G1 fraction ranged from 37% to 42% for controlled H460 cells and cells
treated with As2O3 and/or DDP. FCM and TUNEL staining illustrated that the combination of
As2O3 and DDP provoked synergistic effects on apoptosis induction based on the analysis of the
apoptosis index. Western blotting revealed that the expression of cell cycle related protein p21
and cyclin D1 were not affected by the treatments, whereas apoptosis related protein bax, Bcl-2,
and clusterin were significantly regulated by As2O3 and/or DDP treatments compared with
controls. The expression of caspase-3 in cells treated with the combination of As2O3 and DDP did
not differ from that in cells treated with a single agent.
Conclusion: As2O3 exerted synergistic effects with DDP on NSCLC cells, and the synergistic
effects were partly due to the induction of caspase-independent apoptosis.
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Background
Lung cancer is the number one cause of cancer mortality
in both males and females worldwide [1]. Despite multi-
disciplinary treatment, lung cancer is still a highly lethal
disease due to late detection and resistance to chemother-
apy. The identification of new therapeutic agents that
exert synergistic effects in combination with traditional
cytotoxic agents is an alternative strategy for the systemic
treatment of lung cancer.
Recent evidence indicates that arsenic trioxide (As2O3)
may induce clinical remission in patients with acute pro-
myelocytic leukemia (APL), and several investigations
show that As2O3 induced programmed cell death in APL
cell lines [2-5]. DDP, a platinum-containing anticancer
drug, is one of the most commonly used cytotoxic agents
for the treatment of lung cancer. Due to the poor thera-
peutic effects of current cytotoxic-agents on lung cancer,
the ability of As2O3 to induce apoptosis in non-small cell
lung cancer cells was explored in the present study, and
the synergistic effects of As2O3 with DDP on A549 and
H460 lung cancer cells were analyzed.
Methods
Cell culture and reagents
Human lung cancer A549 and H460 cell lines were
obtained from the ATCC and maintained in RPMI 1640
medium with 10% fetal bovine serum and 1% penicillin.
As2O3  was purchased from Yida Pharmaceutical
Co.(GMP, Ha'erbin, PR. China) and DDP was from Bris-
tol-Myers Squibb Co.(Shanghai, PR. China).
MTT assay
Briefly, cells were seeded at a density of 2,000 to 5,000
cells/well in 96-well plates and incubated overnight. After
treatment with As2O3, DDP, or their combination
(described below), 3-(4, 5-methylthiazol-2-yl)-2, 5-
diphenyl-tetrazolium bromide (MTT) was added (50 μL/
well) for 4 hours. Solubilization of the converted purple
formazan dye was accomplished by placing cells in 100 μL
of 0.01 N HCl/10% SDS and incubating them overnight
at 37°C. The reaction product was quantified by absorb-
ance at 570 nm. All samples were repeated three times,
and data were analyzed by Student's t test.
In vitro clonogenic assay
Human lung carcinoma cells were counted after trypsini-
zation. Cells were serially diluted to appropriate concen-
trations and removed into 25-cm2 flasks in 5-mL medium
in triplicate per data point. After various treatments, cells
were maintained for 8 days. Cells were then fixed for 15
minutes with a 3:1 ratio of methanol:acetic acid and
stained for 15 minutes with 0.5% crystal violet (Sigma) in
methanol. After staining, colonies were counted by the
naked eye, with a cutoff of 50 viable cells. Error bars rep-
resent ± SE by pooling of the results of three independent
experiments. Surviving fraction was calculated as (mean
colony counts)/(cells inoculated)*(plating efficiency),
where plating efficiency was defined as mean colony
counts/cells inoculated for untreated controls.
Cell cycle and apoptosis analysis
Flow cytometry analysis of DNA content was performed
to assess the cell cycle phase distribution as described pre-
viously[6]. Cells were harvested and stained for DNA con-
tent using propidium iodide fluorescence. The computer
program Multicycle from Phoenix Flow System (San
Diego, CA, USA) was used to generate histograms which
were used to determine the cell cycle phase distribution
and apoptosis. TUNEL staining was also used to detect
apoptosis as described previously [7]. The TUNEL stained
apoptotic cells were separately numbered in four ran-
domly selected microscopic fields (400*) and graphed.
Western blot
After various treatments, cells were washed with ice-cold
PBS twice before the addition of lysis buffer (20 mM Tris,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM
sodium NaPPi, 1 mM phenylmethylsulfonyl fluoride, and
leupeptin). Protein concentrations were quantified sepa-
rately by the Bio-Rad Bradford assay. Equal amounts of
protein were loaded into each well and separated by 10%
SDS PAGE, followed by transfer onto nitrocellulose mem-
branes. Membranes were blocked using 5% nonfat dry
milk in PBS for 1 hour at room temperature. The blots
were then incubated with anti-p21, anti-cyclin D1, anti-
bax, anti-bcl-2, anti-clusterin, and anti-caspase-3 antibod-
ies (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C
overnight. Blots were then incubated in secondary anti-
body conjugated with HRP (1:1000; Santa Cruz Biotech-
nology) for 1 hour at room temperature.
Immunoblots were developed using the enhanced chemi-
luminescence (ECL) detection system (Amersham, Piscat-
away, NJ) according to the manufacturer's protocol and
autoradiography.
Results
As2O3 exerted synergistic effects with DDP on the 
proliferation of A549 and H460
The MTT assay showed that 10-2 μM to 10 μM inhibited
the proliferation of A549 and H460 at 72 hours (Fig. 1).
In vitro clonogenic assay proved 10-1 μM to 12.5 μM
As2O3 inhibited the proliferation of A549 and H460 cells
(Fig. 2). MTT assay results showed that 2.5 μM As2O3 and
3  μg/ml DDP exerted synergistic inhibition effects on
A549 and H460 cells at 48 hours. (Fig. 3A,B). To confirm
the synergistic effects of As2O3 with DDP CalcuSyn™ pro-
gram (Version 2.0, Biosoft, Inc., UK) was explored to
make dose-effect curves and to determine the combina-Journal of Experimental & Clinical Cancer Research 2009, 28:110 http://www.jeccr.com/content/28/1/110
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tion indices (CI) (Fig. 4A,B). The CI for A549 and H460
were 0.5 and 0.6, respectively which confirmed the syner-
gism of As2O3 with DDP.
As2O3 did not significantly affect the cell cycles of A549 
and H460 cells
A549 cells were treated with 2.5 μM As2O3 and/or 3 μg/ml
DDP for 48 hours. FCM cell cycle analysis showed that the
treatment of As2O3 and/or DDP did not significantly alter
G0/G1 fractions of A549 cells compared with those of the
control. The G0/G1 fraction ranged from 57% to 62% for
controlled A549 cells and cells treated with As2O3 and/or
DDP; the G0/G1 fraction ranged from 37% to 42% for
controlled H460 cells and cells treated with As2O3 and/or
DDP (Fig. 5). Western blot analysis showed that As2O3
and/or DDP did not affect the expression of cell cycle
related protein p21 and cyclin D1 (data not shown).
As2O3 and/or DDP induced apoptosis of A549 and H460 
cells
A549 cells were treated with 2.5 μM As2O3 and/or 3 μg/ml
DDP for 48 hours. FCM analysis showed the apoptotic
indices (AI) for the controlled A549 cells and cells treated
with As2O3, DDP, or the combination were 0.25 ± 0.01%,
10.6 ± 0.53%, 15.85 ± 0.79%, and 20 ± 1%, respectively.
The AI for the controlled H460 cells and cells treated with
As2O3, DDP, or the combination were 1.95 ± 0.11%, 13.6
± 0.65%, 7.53 ± 0.43%, and 35.6 ± 1.71%, respectively
(Fig. 6). As2O3 and DDP significantly increased the AI
compared with the control cells. TUNEL staining was per-
formed to further confirm AI results from FCM analysis.
With TUNEL staining, the AI for the control A549 cells,
cells treated with As2O3, DDP, or the combination were
3.1 ± 0.16%, 15.41 ± 0.77%, 14 ± 0.7%, and 30 ± 1.5%,
respectively. The AI for the control H460 cells, cells treated
with As2O3, DDP, or the combination were 5.95 ± 0.25%,
18.6 ± 1.13%, 9.53 ± 0.49%, and 40.6 ± 2.11%, respec-
tively (Fig. 7). Western blot analysis showed Bax expres-
Dose response curves for effects of As2O3 on A549 and  H460 lung cancer cell proliferation Figure 1
Dose response curves for effects of As2O3 on A549 
and H460 lung cancer cell proliferation. Cells were 
treated with different concentrations of As2O3 (10-6–10 μM) 
for 72 hours. Proliferation was analyzed by MTT assay. 
As2O3 concentrations of 10-2 μM to 10 μM inhibited A549 
cell proliferation at 72 hours.
Clonogenic assay of the effects of As2O3 on the proliferation  of A549 and H460 cells Figure 2
Clonogenic assay of the effects of As2O3 on the prolif-
eration of A549 and H460 cells. In vitro clonogenic assays 
showed that 10-1 μM to 12.5 μM As2O3 inhibited the prolifer-
ation of A549 and H460 cells. Surviving fraction was calcu-
lated as (mean colony counts)/(cells inoculated) × (plating 
efficiency), where plating efficiency was defined as mean col-
ony counts/cells inoculated for untreated controls.
Synergistic effects of As2O3 and DDP in lung cancer cell lines Figure 3
Synergistic effects of As2O3 and DDP in lung cancer 
cell lines. A. The synergistic effect of As2O3 and DDP in the 
treatment of A549 cells. MTT assay results showed that 2.5 
μM As2O3 and 3 μg/ml DDP exerted synergistic inhibition 
effects on A549 cells at 48 hours. B. The synergistic effect of 
As2O3 and DDP in the treatment of H460 cells. MTT assay 
results showed that 2.5 μM As2O3 and 3 μg/ml DDP exerted 
synergistic inhibition effects on H460 cells at 48 hours.Journal of Experimental & Clinical Cancer Research 2009, 28:110 http://www.jeccr.com/content/28/1/110
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Dose effect curve for A549 (A) and H460 (B) cells Figure 4
Dose effect curve for A549 (A) and H460 (B) cells. 
The concentration of DDP was 3 μg/ml and the concentra-
tion for As2O3 ranged from 0.1 μM to 12.5 μM. CalcuSyn™ 
(Version 2.0, Biosoft, Inc., UK) was used for dose-effect 
curves and to determine the combination indices (CI).
G0/G1 fraction analysis Figure 5
G0/G1 fraction analysis. FCM cell cycle analysis showed 
that the treatment of As2O3 and/or DDP did not significantly 
affect G0/G1 fractions of A549 and H460 cells compared 
with those of the control. The G0/G1 fraction ranged from 
57% to 62% for control A549 cells and for A549 cells treated 
with As2O3 and/or DDP, and from 37% to 42% for control 
H460 cells and for H460 cells treated with As2O3 and/or 
DDP.
FCM cell cycle analysis of apoptotic index (AI) for cells  treated with As2O3 and/or DDP Figure 6
FCM cell cycle analysis of apoptotic index (AI) for 
cells treated with As2O3 and/or DDP. AI for the control 
A549 cells and cells treated with As2O3, DDP, or the combi-
nation were 0.25 ± 0.01%, 10.6 ± 0.53%, 15.85 ± 0.79%, and 
20 ± 1%, respectively; the AI for the control H460 cells and 
cells treated with As2O3, DDP, or the combination were 
1.95 ± 0.11%, 13.6 ± 0.65%, 7.53 ± 0.43%, and 35.6 ± 1.71%, 
respectively.
TUNEL staining analysis Figure 7
TUNEL staining analysis. With TUNEL staining, the AI 
for the control A549 cells and cells treated with As2O3, 
DDP, or the combination were 3.1 ± 0.16%, 15.41 ± 0.77%, 
14 ± 0.7%, and 30 ± 1.5%, respectively; the AI for the control 
H460 cells and cells treated with As2O3, DDP, or the combi-
nation were 5.95 ± 0.25%, 18.6 ± 1.13%, 9.53 ± 0.49%, and 
40.6 ± 2.11%, respectively.Journal of Experimental & Clinical Cancer Research 2009, 28:110 http://www.jeccr.com/content/28/1/110
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Western blot analysis of Bax expression in lung cancer cell after different treatments Figure 8
Western blot analysis of Bax expression in lung cancer cell after different treatments. Bax expression was 2-fold 
greater in A549 cells treated with As2O3 and DDP than in control cells. Bax expression was 3.7-fold greater in H460 cells 
treated with As2O3 and DDP than in control cells.
Western blot analysis of Bcl-2 expression in lung cancer cells after different treatments Figure 9
Western blot analysis of Bcl-2 expression in lung cancer cells after different treatments. Bcl-2 expression was 72% 
less in As2O3 and DDP-treated A549 cells than in controls, and it 25% less in As2O3 and DDP-treated H460 cells than in con-
trols.Journal of Experimental & Clinical Cancer Research 2009, 28:110 http://www.jeccr.com/content/28/1/110
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sion increasing by 2-fold in the A549 cells treated with
As2O3 and DDP over levels in control cells. In H460 cells
treated with As2O3 and DDP, Bax expression was 3.7 times
greater than in the control (Fig. 8). Bcl-2 expression was
72% less in the As2O3 and DDP treated A549 cells than in
control cells, and 25% less in the As2O3 and DDP treated
H460 cells than in control cells (Fig. 9). Expression of
another tumor suppressed protein, clusterin, was 70% less
in the As2O3 and DDP treated A549 cells than in control
cells, and in H460 cells, clusterin expression was 90% less
with treatment with the combination of As2O3 and DDP
than in control cells (Fig. 10). For both A549 and H460,
caspase-3 expression increased with the treatment of
As2O3  and/or DDP over control levels, but caspase-3
expression was not different in cells treated with the com-
bination of As2O3 and DDP and cells treated with each
single agent (Fig. 11).
Discussion and conclusion
Our in vitro study showed that As2O3 is an effective reagent
that inhibits the proliferation of A549 and H460 lung can-
cer cells. As2O3 cytotoxicity was due to the induction of
apoptosis but not cell cycle arrest. FCM and TUNEL assay
analyses showed that As2O3 significantly induced apopto-
sis. When As2O3 and DDP were combined, a synergistic
effect was found in the treatment of A549 and H460 cells.
Protein assays showed that the combination of As2O3 and
DDP affected apoptosis-related proteins such as Bcl-2,
Bax, and clusterin but not caspase-3, while the use of each
single agent did not. The changes in apoptosis-related pro-
tein expression partly contributed to the effect of As2O3 on
lung cancer cells.
Since lung cancer is a lethal disease due to late detection
and resistance to chemotherapy, this study was conducted
to determine whether As2O3 could exert synergistic effects
in combination with traditional cytotoxic-agents on lung
cancer cell death. Although As2O3 has been an effective
treatment for the acute promyelocytic leukemia, the
mechanism by which As2O3 induces cell death remains
poorly understood. Recent reports suggest that As2O3
causes DNA damage, oxidative stress, and mitochondrial
dysfunction [8,9]. In addition, As2O3 treatment results in
cell-cycle arrest in MCF-7 HeLa cells [10]; however, our
results demonstrate that cell cycle is not significantly
affected by As2O3, since the G1/0 fraction and cell cycle-
related protein expression did not change significantly
with As2O3 treatment. The inconsistency between these
findings may be due to different mechanisms of action by
As2O3 in various cell lines. Our results were consistent
Western blot analysis of clusterin expression in lung cancer cells after different treatments Figure 10
Western blot analysis of clusterin expression in lung cancer cells after different treatments. Clusterin expression 
was 70% less in As2O3 and DDP-treated A549 cells than in controls, and in H460 cells, clusterin expession was 90% less with 
treatment of the combination of As2O3 and DDP than in controls.Journal of Experimental & Clinical Cancer Research 2009, 28:110 http://www.jeccr.com/content/28/1/110
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with previous studies that indicated that proapoptotic Bcl-
2 family members, Bcl-2 and Bax, are involved in the
apoptosis of cancer cells induced by As2O3 [11,12]. Previ-
ous studies show that clusterin is a caspase-independent
apoptosis-related protein and it is a potential target in the
treatment of non-small cell lung cancer [13-15]. Here, we
showed that the synergistic effects of As2O3 and DDP
might be due, in part, to clusterin-mediated apoptosis.
Depending on the cell system investigated, As2O3-
induced cell death has been associated with caspase-
dependent apoptosis, as well as caspase-independent
death pathways [16-18]. In this study, the combination of
As2O3 and DDP increased caspase-3 expression, which
indicates that caspase might be involved in apoptosis
induced by As2O3 or DDP. However, the combination of
As2O3 and DDP did not affect caspase-3 expression com-
pared with cells treated with a single agent, which suggests
that the synergistic effects are more likely to be caspase-
independent. This study showed caspase-independent
death pathways that involved Bcl-2, Bax, and clusterin
were the primary mechanism by which As2O3 exerts syn-
ergistic effects with DDP on NSCLC cells.
In conclusion, As2O3 exerted synergistic effects with DDP
on lung cancer cells. The proliferation inhibition might be
partly due to the induction of apoptosis. Based on our
study, As2O3 may be a promising agent in the treatment of
lung cancer, although further in vitro and in vivo studies
are necessary to elucidate the mechanism by which As2O3
induces apoptosis.
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